Olema Oncology Raises $85 Million in Series C Financing to Advance Clinical Development of OP-1250 in Breast Cancer

- Financing in Support of Company's Goal of Developing Targeted Therapies to Improve the Lives of Women with Cancer

- Lead Investor Vivo Capital is Joined by Additional New Investors Avoro Capital Advisors, Funds and Accounts Managed by BlackRock, Deerfield Management Company and OrbiMed, and All Existing Institutional Investors

SAN FRANCISCO, October 1, 2020-- Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced the closing of a $85 million Series …